Peripheral Vascular Disease 

Updated: May 24, 2022
Author: Everett Stephens, MD; Chief Editor: Erik D Schraga, MD 

Overview

Background

Peripheral vascular disease (PVD) is a nearly pandemic condition that has the potential to cause loss of limb or even loss of life. PVD manifests as insufficient tissue perfusion initiated by existing atherosclerosis acutely compounded by either emboli or thrombi. Many people live daily with significant degrees of PVD; however, in settings such as acute limb ischemia, this latent disease can suddenly become life-threatening and necessitate emergency intervention to minimize morbidity and mortality.[1, 2]

For patient education information, see Peripheral Vascular Disease.

Pathophysiology

PVD, also known as arteriosclerosis obliterans, is primarily the result of atherosclerosis. The atheroma consists of a core of cholesterol joined to proteins with a fibrous intravascular covering. The atherosclerotic process may gradually progress to complete occlusion of medium-sized and large arteries. The disease typically is segmental, with significant variation from patient to patient.

Vascular disease may manifest acutely when thrombi, emboli, or acute trauma compromises perfusion. Thromboses are often of an atheromatous nature and occur in the lower extremities more frequently than in the upper extremities. Multiple factors predispose patients to thrombosis. These factors include sepsis, hypotension, low cardiac output (see the Cardiac Output calculator), aneurysms, aortic dissection, bypass grafts, and underlying atherosclerotic narrowing of the arterial lumen.

Emboli, the most common cause of sudden ischemia, usually are of cardiac origin (80%); they also can originate from proximal atheroma, tumor, or foreign objects. Emboli tend to lodge at artery bifurcations or in areas where vessels abruptly narrow. The femoral artery bifurcation is the most common site (43%), followed by the iliac arteries (18%), the aorta (15%), and the popliteal arteries (15%).

The site of occlusion, the presence of collateral circulation, and the nature of the occlusion (thrombus or embolus) determine the severity of the acute manifestation. Emboli tend to carry higher morbidity because the extremity has not had time to develop collateral circulation. Whether caused by embolus or thrombus, occlusion results in both proximal and distal thrombus formation as a consequence of flow stagnation.

Prognosis

Female sex appears to have an effect on outcomes after lower-extremity interventions for peripheral arterial disease (PAD). In a retrospective study (2004-2009) evaluating data from 12,379 patients (41% women) in 16 centers participating in the Blue Cross Blue Shield of Michigan Cardiovascular Consortium PVI registry who underwent these procedures, female sex was associated with a higher rate of vascular complications, transfusions, and embolism, but no differences wer eseen for inpatient mortality, myocardial infarction (MI), or stroke or transient ischemic attack.[3] Despite the higher complication rates in women, the investigators reported similar overall procedural success rates between the sexes.

In another retrospective study that evaluated data over 6 years from 23,870 index transfemoral vascular access procedures from cross-matching the Eastern Danish Heart Registry with the Danish Vascular Registry, Dencker et al noted a low risk of major vascular complications (0.54%) with femoral access following coronary angiography and percutaneous coronary intervention (PCI).[4] Risk factors for such complications included left-side access, the presence of PAD, and female sex.[4]

 

Presentation

History

The primary factor for developing peripheral vascular disease (PVD) is atherosclerosis.

Other conditions that often coexist with PVD are coronary artery disease (CAD), atrial fibrillation, cerebrovascular disease, and renal disease. PVD that coexists with CAD may indicate an increased burden of atheroma.[5] Studies have suggested that even asymptomatic peripheral arterial disease (PAD) is associated with increased CAD mortality.[6] Noninvasive tests for vascular disease—pulse wave velocity and ankle-brachial index (ABI)—have been linked with the number of vessels obstructed with CAD.[7]

Risk factors for PVD include smoking, hyperlipidemia, diabetes mellitus, and hyperviscosity.

Other etiologies for developing PVD may include phlebitis, injury or surgery, and autoimmune disease, including vasculitides, arthritis, or coagulopathy. PVD rarely exhibits an acute onset; it instead manifests a more chronic progression of symptoms. Patients with acute emboli causing limb ischemia may have new or chronic atrial fibrillation, valvular disease, or recent myocardial infarction (MI), whereas a history of claudication, rest pain, or ulceration suggests thrombosis of existing PVD. Radiation-induced PAD is becoming more common, perhaps because of the efficacy of current antineoplastic treatment and increased survival.[8]

Intermittent claudication may be the sole manifestation of early symptomatic PVD. The level of arterial compromise and the location of the claudication are closely related, as follows:

  • Aortoiliac disease manifests as pain in the thigh and buttock, whereas femoropopliteal disease manifests as pain in the calf
  • Symptoms are precipitated by walking a predictable distance and are relieved by rest
  • Collateral circulation may develop, reducing the symptoms of intermittent claudication, but failure to control precipitant factors and risk factors often causes its reemergence
  • Claudication may also present as the hip or leg "giving out" after a certain period of exertion and may not demonstrate the typical symptom of pain on exertion
  • The pain of claudication usually does not occur with sitting or standing

Ischemic rest pain is more worrisome; it refers to pain in the extremity that is due to a combination of PVD and inadequate perfusion. Ischemic rest pain often is exacerbated by poor cardiac output. The condition is often partially or fully relieved by placing the extremity in a dependent position, so that perfusion is enhanced by the effects of gravity.

Erectile dysfunction (ED) has been linked as a potential early indicator of both CAD and PVD.[9] Whereas many factors can contribute to ED (including obesity, lifestyle, physical activity, diabetes, and psychiatric factors), the etiology of the vasculogenic cause of ED parallels the etiology of CAD and PVD.

Leriche syndrome is a clinical syndrome described by intermittent claudication, impotence, and significantly decreased or absent femoral pulses. This syndrome indicates chronic peripheral arterial insufficiency due to narrowing of the distal aorta.

The patient's medications may provide a clue to the existence of PVD. Pentoxifylline is a commonly used medication specifically prescribed for PVD. Daily aspirin commonly is used for prevention of cardiac disease (CAD), but PVD often coexists, to some degree, in patients with CAD.

Physical Examination

A systematic examination of the peripheral vasculature is critical for proper evaluation.

Peripheral signs of peripheral vascular disease are the classic "five P's," as follows:

  • Pulselessness
  • Paralysis
  • Paresthesia
  • Pain
  • Pallor

Paralysis and paresthesia suggest limb-threatening ischemia and mandate prompt evaluation and consultation.

Assess the heart for murmurs or other abnormalities. Investigate all peripheral vessels, including carotid, abdominal, and femoral, for pulse quality and bruit. Note that the dorsalis pedis artery is absent in 5-8% of normal subjects, but the posterior tibial artery usually is present. Both pulses are absent in only about 0.5% of patients. Exercise may cause the obliteration of these pulses.

The Allen test may provide information on the radial and ulnar arteries.

The skin may have an atrophic, shiny appearance and may demonstrate trophic changes, including alopecia; dry, scaly, or erythematous skin; chronic pigmentation changes; and brittle nails.

Advanced PVD may manifest as mottling in a "fishnet pattern" (livedo reticularis), pulselessness, numbness, or cyanosis. Paralysis may follow, and the extremity may become cold; gangrene eventually may be seen. Poorly healing injuries or ulcers in the extremities help provide evidence of preexisting PVD.

The ABI can be determined at the bedside. Pressure is measured with Doppler ultrasonography at the brachial artery and at the posterior tibialis artery. The ankle systolic pressure is divided by the brachial pressure, both as measured in the supine position. Normally, the ratio is greater than 1. In severe disease, it is less than 0.5.

A semiquantitative assessment of the degree of pallor also may be helpful. While the patient is supine, the degree of pallor is assessed. If pallor manifests when the extremity is level, the pallor is classified as level 4. If not, the extremity is raised 60°. If pallor occurs in 30 seconds or less, it is a level 3; if in less than 60 seconds, level 2; and if in 60 seconds, level 1. If no pallor occurs within 60 seconds, it is level 0.

 

DDx

 

Workup

Laboratory Studies

Routine blood tests may be indicated in the evaluation of patients with suspected serious compromise of vascular flow to an extremity. Complete blood count (CBC), blood urea nitrogen (BUN), creatinine, and electrolyte studies help evaluate for signs of end-organ injury and for factors that might lead to worsening of peripheral perfusion. Risk factors for the development of vascular disease (lipid profile, coagulation tests) can also be evaluated, though not necessarily in the emergency department (ED) setting.

Elevated levels of inflammatory blood markers such as D dimer, C-reactive protein, interleukin-6, and homocysteine have been linked to decreased lower extremity tolerance of exercise.[10] Higher levels of activity in daily life have been shown to decrease these levels.[11] The applicability to practice in emergency medicine is not clear, but it is unlikely to be of clinical significance.

See also guidelines from the American Heart Association and American College of Cardiology (AHA/ACC) [12] and the Canadian Cardiovascular Society (CCS).[13]

Imaging Studies

Plain films are of little use in the setting of peripheral vascular disease (PVD).

The criterion standard for intraluminal obstruction has always been arteriography, though it is both potentially risky and often unobtainable in the emergency setting. The delay associated with obtaining arteriography in the setting of obvious limb ischemia can delay definitive treatment to deleterious effect. If time allows, arteriography can prove useful in discriminating thrombotic disease from embolic disease.

Doppler ultrasonographic studies are useful as primary noninvasive studies to determine flow status. Upper extremities are evaluated over the axillary, brachial, ulnar, and radial arteries. Lower extremities are evaluated over the femoral, popliteal, dorsalis pedis, and posterior tibial arteries. Note the presence of Doppler signal and the quality of the signal (ie, monophasic, biphasic, triphasic). The presence of distal flow does not exclude emboli or thrombi because collateral circulation may provide these findings.

Magnetic resonance imaging (MRI) may be of some clinical benefit by virtue of its high visual detail. Plaques are imaged easily, as is the difference between vessel wall and flowing blood. MRI also has the benefits of angiography, providing even higher detail and capable of replacing traditional arteriography. The utility of MRI is limited in the emergency setting, often because of the location of the device and the technical skill required to interpret the highly detailed images.

Computed tomography (CT) can be of use to the emergency physician in  that it does not have the time and availability constraints that MRI does. Although noncontrast studies can be useful for imaging calcification and arteriosclerosis, contrast studies are most useful for imaging arterial insufficiency. Renal function should be confirmed before contrast administration; PVD often coexists with risk factors for contrast-induced renal failure. High-definition CT studies in patients who exhibit symptoms of PVD can be of benefit in guiding treatment decisions and modalities.[14]

CT angiography (CTA) and magnetic resonance angiography (MRA) represent significant developments in axial imaging of PVD. Benefits of CTA include rapid noninvasive acquisition, wide availability, high spatial resolution, and the ability to generate isotropic datasets on 64-detector-row and higher CT scanners; drawbacks include the exposure to iodinated contrast and ionizing radiation. Benefits of MRA include high diagnostic accuracy and the avoidance of exposure to ionizing radiation; drawbacks include limited availability and increased cost.[15]

Molecular imaging with radionuclide-based approaches may potentially provide a novel noninvasive assessment of biologic processes in PVD, such as angiogenesis and atherosclerosis.[16]

See also guidelines from the American Heart Association and American College of Cardiology (AHA/ACC)[12]  and the Canadian Cardiovascular Society (CCS).[13]

Other Tests

Ankle-brachial index

The ankle-brachial index (ABI) is a useful test for comparing pressures in the lower extremity with pressures in the upper extremity. Blood pressure normally is slightly higher in the lower extremities than in the upper. Comparison to the contralateral side may suggest the degree of ischemia.

The ABI is obtained by applying blood pressure cuffs to the calf and the upper arm. The blood pressure is measured, and the systolic ankle pressure is divided by the systolic brachial pressure. Normal ABI is higher than 1; a value less than 0.95 is considered abnormal. This test can be influenced by arteriosclerosis and small-vessel disease (eg, diabetes), which reduce its reliability. Progressive peripheral arterial disease (PAD), indicated by an ABI decline of more than 0.15, has been associated with increased cardiovascular disease risk.[17]

A retrospective study found that the combination of the ABI and percentage of mean arterial pressure (%MAP) improves the diagnostic sensitivity for PAD versus ABI alone in those with an ABI above 0.90.[18]  Analysis was based on medical records from 114 patients (215 limbs) with a diagnosis of PAD based on multiple detector computed tomography angiography (MDCTA). Among the findings were the following[18] :

  • Improved sensitivity from a combination of an ABI < 0.90 and a %MAP ≥42.5% as diagnostic criteria for PAD versus ABI alone
  • Significantly higher PAD risk in individuals with both an ABI < 0.90 and an ABI >0.90 with a %MAP ≥42.5% compared to patients who have ABI >0.90 with a %MAP < 42.5%
  • Improved sensitivity and specificity from a combination of an ABI ≤0.90 and a %MAP ≥42.5% than when using a low or borderline ABI

Transcutaneous oximetry

Transcutaneous oximetry affords assessment of impaired flow secondary to both microvascular and macrovascular disruption. Its use is increasing, especially in the realm of wound care and patients with diabetes. Transcutaneous oximetry has not been studied extensively in emergent occlusion.

Electrocardiography

An electrocardiogram (ECG) may be obtained to look for evidence of dysrhythmia, prior cardiac injury, or even acute myocardial infarction.

See also guidelines from the American Heart Association and American College of Cardiology (AHA/ACC)[12] and the Canadian Cardiovascular Society (CCS).[13]

Procedures

Carotid artery reactivity

A novel procedure that assesses endothelial function appears to have the potential to predict cardiovascular (CV) events in patients with peripheral arterial disease (PAD).[19]  In a study of 172 patients with PAD who underwent carotid artery reactivity, 82 showed carotid constriction and 90 showed carotid dilation. There were more CV events seen in the carotid constriction group than those in the carotid dilation group; moreover, there was a four-fold higher risk for higher CV events and a two-fold higher risk for clinical deterioration even when adjusted for other risk factors.[19]

 

Treatment

Approach Considerations

Therapeutic recommendations include single-agent antiplatelet agents for prevention of cardiovascular events in patients wth asymptomatic and symptomatic peripheral arterial disease (PAD).[2] These medications should be used in conjunction with efforts to reduce risk factors, including smoking cessation and exercise therapy.[20]

Statins have been linked to improved prognosis in other vasculopathies, including renovascular and cardiovascular events.[21]  Although lacking an immediate effect on any vascular process, statins show promise in slowing the progression of atherosclerotic disease systemically.

When conservative measures fail to improve quality of life and function, endovascular procedures are considered.[1] However, the timing and need for revascularization are related to the general primary presentations of claudication, critical limb ischemia, and acute limb ischemia, in which urgent intervention is warranted for critical limb ischemia.[1, 2]

An emerging treatment for peripheral vascular disease (PVD) is the use of growth factor (delivered as genes or proteins) and cell therapy. The delivery of growth factors or cells to the ischemic tissue can locally stimulate the regeneration of the functional vasculature network, reperfuse the ischemic tissue, and salvage the limb.[22]

See also guidelines from the American Heart Association and American College of Cardiology (AHA/ACC)[12] and the Canadian Cardiovascular Society (CCS).[13]

Prehospital and Emergency Department Care

Prehospital care for PVD involves the basics: control ABCs (airway, breathing, circulation), obtain intravenous access, and administer oxygen. In general, do not elevate the extremity. Note and record the distal pulses and skin condition. Perform and document a neurologic examination of the affected extremities.

Early emergency department care involves attention to the ABCs, intravenous access, and obtaining baseline laboratory studies. Obtain an electrocardiogram (ECG) and a chest radiograph.

Treatment of either thrombi or emboli in the setting of peripheral vascular disease is similar. Empirically, initiate a heparin infusion with the goal of increasing activated partial thromboplastin time to 1.5 times normal levels. Acute leg pain correlated with a cool distal extremity, diminished or absent distal pulses, and an ankle blood pressure less than 50 mm Hg should prompt consideration of emergent surgical referral.

In some cases of emboli, intra-arterial thrombolytic agents may be useful. The exact technique of administration varies, in both dosage and time of administration. Remember that intra-arterial thrombolysis remains investigational. Obviously, such thrombolytic therapy is contraindicated in the presence of active internal bleeding, intracranial bleeding, or bleeding at noncompressible sites.

Surgical Care

Early surgical consultation in patients with acute limb ischemia is prudent. Depending on the case, the surgeon may involve interventional radiology or proceed operatively. Emboli may be treated successfully by Fogarty catheter (ie, an intravascular catheter with a balloon at the tip). The balloon is passed distal to the lesion; the balloon is inflated, and the catheter is withdrawn along with the embolus. This technique most commonly is used for iliac, femoral, or popliteal emboli.

Definitive treatment of hemodynamically significant aortoiliac disease usually takes the form of aortobifemoral bypass, which has a 5-year patency rate of approximately 90%. Those patients in whom peripheral vascular disease (PVD) becomes significant, however, often have a plethora of comorbid medical conditions, such as cardiovascular disease, diabetes, and chronic obstructive pulmonary disease, which increase procedural morbidity and mortality. Axillobifemoral bypass and femorofemoral bypass are alternatives, both of which have lower 5-year patency rates but have lower procedural mortality.

In a retrospective study that evaluated the long-term outcomes of 714 patients who underwent percutaneous procedures for popliteal and infrapopliteal peripheral arterial disease, those with diabetes (n = 418; 58.5%) were younger and had a higher prevalence of a history of coronary artery disease, heart failure, end-stage renal disease, and a previous contralateral limb amputation relative to nondiabetic patients.[23] Independent of baseline comorbidities, diabetes was associated with significantly higher all-cause mortality, ipsilateral major amputation, and major adverse events.

A systematic review and meta-analysis of data from five databases over a period of 20 years (2000-2019) included 17 observational studies with 13,140 patients to examine outcomes of lower extremity peripheral arterial interventions in those with and without chronic kidney disease (CKD) and/or end-stage renal disease (ESRD) relative to individuals with normal renal function.[24] Patients with CKD/ESRD had a higher incidence of target lesion revascularization, major amputations, and long-term mortality; these data were statistically significant for the latter two factors, regardless of the type of intervention (endovascular vs open surgery). However, the higher rates of target lesion revascularization in those with CKD/ESRD were only seen with endovascular interventions; there were no differences for open surgical approaches.[24]

In a study that assessed the long-term clinical impact of post endovascular therapy ABI improvement for peripheral arterial disease in 1307 consecutive patients (710 aortoiliac and 597 femoropopliteal lesions), investigators found that an increase of ABI of at least 0.15 following a successful procedure was independently predictive of "freedom from a composite of target limb revascularization and major amputation, irrespective of the locations of the treated lesions and the preprocedural ABI."[25]  

Some areas of arteriostenosis can be revascularized with percutaneous transluminal coronary angioplasty (PTCA). If the occlusion is complete, a laser may be useful in making a small hole through which to pass the balloon. Restenosis is a concern with PTCA, particularly for larger lesions. Stents and lasers are still considered experimental.

An initial study showed promise in relieving the pain of PAD with topically applied lidocaine spray. Suzuki et al studied 24 subjects with PAD and noted a significant drop in pain associated with PAD by applying an 8% lidocaine metered dose spray to the affected areas. Blood levels of lidocaine were minimal, and this technique may have therapeutic potential for those affected with focal PAD pain.[26]

Long-Term Monitoring

Patients who have significant PVD but whose illness is not so severe or acute that it requires inpatient treatment may be discharged with appropriate follow-up. However, counsel these patients regarding the potential effects of various activities and medications on the course of their illness. Advise patients to stop smoking and to avoid cold exposures and medications that can lead to vasoconstriction, including medications used for migraines and over-the-counter medications.

Some recreational drugs (eg, cocaine) may have a deleterious effect on peripheral arterial tone, and beta-blockers may exacerbate the condition.

Consultation with providers who will be following the patient after discharge from the emergency department is advised when making decisions regarding the discontinuance of medications used for chronic medical conditions.

 

Guidelines

CCS Guidelines on Peripheral Arterial Disease

Guidelines on peripheral arterial disease (PAD) were published in May 2022 by the Canadian Cardiovascular Society in the Canadian Journal of Cardiology.[13] They include approaches to the diagnosis, risk stratification, and medical and intervention treatments for patients with PAD. Strong recommendations are outlined below.

Diagnosis and Screening

Use an ankle-brachial index (ABI) and/or toe-brachial index (TBI) to confirm PAD in symptomatic patients.

A broad, population-based PAD screening strategy is not recommended for individuals without claudication signs/symptoms.

Management

Smoking cessation is recommended to prevent PAD, as well as to prevent major adverse cardiovascular (CV) events (MACE) and major adverse limb events (MALE) in those with PAD. Recommended smoking cessation interventions include but are not limited to intensive counselling; pharmacotherapy (eg, nicotine replacement therapy [NRT], bupropion, varenicline); and, occasionally, nicotine-containing e-cigarettes.

Offer a sodium-glucose cotransporter 2 inhibitor (SGLT-2I) to diabetic patients with PAD rather than usual diabetic control for MACE reduction without a rise in amputation risk.

Administer lipid-modifying therapy to patients with PAD to lower death and CV death, nonfatal myocardial infarction (MI) and nonfatal stroke (MACE), and MALE. Use the maximally tolerated statin therapy. Use statin add-on therapies (ezetimibe and/or proprotein convertase subtilisin/kexin-9 inhibitors [PCSK-9Is]) if, while on maximally tolerated statin therapy, the level of low-density lipoprotein cholesterol (LDL-C) is ≥1.8 mmol/L, of non-high-density lipoprotein cholesterol (non-HDL-C) is ≥2.4 mmol/L, or of apolipoprotein B100 is ≥0.7 mg/dL.

For those with PAD on maximally tolerated statin therapy but have a triglyceride level of 1.5-5.6 mmol/L, consider using icosapent ethyl to reduce CV death, nonfatal MI, and nonfatal stroke.

Unless there are contraindications, first-line treatment of hypertension in PAD is angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

Routine antithrombotic therapy (antiplatelet or anticoagulant) is not recommended for those with isolated asymptomatic lower extremity (LE) PAD.

For patients with symptomatic LE PAD and who are:

  • At high risk for ischemic events (high-risk comorbidities [eg, polyvascular disease, diabetes, heart failure history, renal insufficiency]) and/or high-risk limb presentation (following peripheral revascularization, limb amputation, rest pain, ischemic ulcers), and at low bleeding risk: Use rivaroxaban 2.5 mg twice daily (BID) with aspirin (80-100 mg daily)
  • At low bleeding risk and without high-risk limb comorbidities or high-risk limb presentation: Use rivaroxaban 2.5 mg BID with aspirin or single antiplatelet therapy (SAPT)
  • At high bleeding risk and still eligible for antithrombotic therapy: Consider SAPT with aspirin (75-325 mg) or clopidogrel (75 mg)

For those with stable LE PAD, additional full-dose anticoagulation with antiplatelet therapy is not recommended to reduce MACE and MALE events.

Administer rivaroxaban 2.5 mg BID daily with aspirin (80-100 mg daily) for patients with LE PAD after elective open revascularization, and with or without short-term clopidogrel for elective endovascular revascularization.

For those with PAD and intermittent claudication, supervised exercise programs are first-line therapy to improve maximal and pain-free walking distance and time, as well as quality of life (QoL); walking is the preferred form of exercise in exercise programs. When there are no available supervised exercise programs or when not desired by the patient, offer a structured home-based or community exercise program to improve leg symptoms and QoL.

Revascularization Interventions

The Revised Cardiac Risk Index (RCRI) is not recommended for preoperative evaluation of cardiac risk and 30-day mortality in peripheral arterial surgery.

Revascularization is not recommended for those with asymptomatic PAD.

Selection of the revascularization procedure should be specific to the patient, expected to have low perioperative morbidity, and be reasonably likely to provide sustained symptomatic benefit. Selection of endovascular versus open revascularization strategies for PAD should take into account anatomic, patient, and procedural factors, as well as operator expertise and resource availability.

For patients with chronic limb-threatening ischemia:

  • Provide urgent referral to vascular specialists for consideration of revascularization
  • Consider endovascular, open, or hybrid revascularization on the basis of the anatomic disease pattern, degree of ischemia, expected procedure durability, perioperative risk, and patient life expectancy
  • Primary major amputation is recommended for those with nonreconstructible disease, nonsalvageable limb, nonambulatory status, severe sepsis, or for palliation for those with a short life expectancy and who are not suitable revascularization candidates

Depending on the severity of tissue loss, gangrene, and/or infection, wound debridement and/or minor amputation concurrent with revascularization or in a staged manner is recommended.

Endovascular therapy is recommended for appropriately selected patients with claudication or chronic limb-threatening ischemia.

Endovascular therapy is not recommended in the common femoral or profunda femoris arteries; for lesions in asymptomatic patients; and for nonhemodynamically significant lesions.

Surgical revascularization

For intermittent claudication, perform surgical bypass to the popliteal artery (when indicated) with an autogenous vein preferred over prosthetic graft material. Femoral-tibial artery bypasses are not recommended.

For chronic limb-threatening ischemia, perform surgical bypass to the popliteal or infrapopliteal arteries with an autogenous vein. In those with chronic limb-threatening for whom endovascular revascularization is not feasible and a suitable autogenous vein is not available, prosthetic material can be effective for bypass to the below-knee popliteal and tibial arteries as a last resort in cases of limb salvage.

AHA/ACC Guideline on Lower-Extremity Peripheral Artery Disease

In November 2016, the American Heart Association (AHA) and the American College of Cardiology (ACC) published the following recommendations on lower-extremity peripheral artery disease (PAD)[12] :

  • The vascular examination for PAD includes pulse palpation, auscultation for femoral bruits, and inspection of the legs and feet; lower-extremity pulses are assessed and rated as follows: 0, absent; 1, diminished; 2, normal; or 3, bounding
  • To confirm the diagnosis of PAD, abnormal physical examination findings must be confirmed with diagnostic testing, generally with the ankle-brachial index (ABI) as the initial test
  • Patients with confirmed diagnosis of PAD are at increased risk for subclavian artery stenosis; an inter-arm blood pressure difference of >15 to 20 mm Hg is abnormal and suggestive of subclavian (or innominate) artery stenosis; measuring blood pressure in both arms identifies the arm with the highest systolic pressure, a requirement for accurate measurement of the ABI
  • Resting ABI results should be reported as abnormal (ABI ≤0.90), borderline (ABI 0.91-0.99), normal (1.00-1.40), or noncompressible (ABI >1.40)
  • ABI is not recommended in patients who are not at increased risk of PAD and who do not have a  history or physical examination findings suggestive of PAD
  • Toe-brachial index (TBI) should be measured to diagnose patients with suspected PAD when the ABI is >1.40
  • Patients with exertional non–joint-related leg symptoms and normal or borderline resting ABI (>0.90 and ≤1.40) should undergo exercise treadmill ABI testing to evaluate for PAD
  • Patients with PAD should receive a comprehensive program of guideline-directed medical therapy, including structured exercise and lifestyle modification, to reduce cardiovascular ischemic events and improve functional status
  • Antiplatelet therapy with aspirin alone (range, 75-325 mg/day) or clopidogrel alone (75 mg/day) is recommended to reduce myocardial infarction (MI), stroke, and vascular death in patients with symptomatic PAD
  • Treatment with a statin medication is indicated for all patients with PAD
  • Patients with PAD who smoke cigarettes or use other forms of tobacco should be advised at every visit to quit
  • Cilostazol is an effective therapy to improve symptoms and increase walking distance in patients with claudication
  • Endovascular procedures are effective as a revascularization option for patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease
  • When surgical revascularization is performed, bypass to the popliteal artery with autogenous vein is recommended in preference to prosthetic graft material 
 

Medication

Medication Summary

The goal of pharmacotherapy is to reduce morbidity and to prevent complications.

Anticoagulants

Class Summary

Anticoagulants reduce thrombin generation and fibrin formation and minimize clot propagation.

Heparin

Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Does not actively lyse but is able to inhibit further thrombogenesis. Prevents reaccumulation of clot after spontaneous fibrinolysis.

 

Questions & Answers

Overview

What is peripheral vascular disease (PVD)?

What causes peripheral vascular disease (PVD)?

What are the manifestations of peripheral vascular disease (PVD)?

What is the role of emboli in the pathophysiology of peripheral vascular disease (PVD)?

What factors affect the severity of an acute manifestation of peripheral vascular disease (PVD)?

Is the prognosis of peripheral vascular disease (PVD) different for men and women?

What is the risk of complications in peripheral vascular disease (PVD)?

Presentation

What is the role of medication history in the evaluation for peripheral vascular disease (PVD)?

What is the primary risk factor for peripheral vascular disease (PVD)?

Which conditions commonly coexist with peripheral vascular disease (PVD)?

What are the main risk factors for peripheral vascular disease (PVD)?

What are less common causes of peripheral vascular disease (PVD)?

How is intermittent claudication characterized in peripheral vascular disease (PVD)?

What is the significance of ischemic rest pain in peripheral vascular disease (PVD)?

What is the relationship between erectile dysfunction (ED) and peripheral vascular disease (PVD)?

What is the role of Leriche syndrome in peripheral vascular disease (PVD)?

What is the role of a peripheral vasculature exam in the evaluation of peripheral vascular disease (PVD)?

What are the peripheral signs of peripheral vascular disease (PVD)?

What do paralysis and paresthesia indicate in the exam for peripheral vascular disease (PVD)?

How is a cardiac assessment performed in the physical exam for peripheral vascular disease (PVD)?

Why is an Allen test performed in the physical exam for peripheral vascular disease (PVD)?

How is the appearance of the skin characterized in peripheral vascular disease (PVD)?

What are the signs of advanced peripheral vascular disease (PVD)?

What is the role of an ankle-brachial index in an exam for peripheral vascular disease (PVD)?

How is pallor quantified in the assessment of peripheral vascular disease (PVD)?

DDX

What are the differential diagnoses for Peripheral Vascular Disease?

Workup

Which lab tests are indicated in the workup of peripheral vascular disease (PVD)?

What do elevated levels of inflammatory blood markers indicate in the workup of peripheral vascular disease (PVD)?

Is plain radiography indicated in the workup of peripheral vascular disease (PVD)?

What is the role of arteriography in the workup of peripheral vascular disease (PVD)?

What is the role of Doppler ultrasonography in the workup of peripheral vascular disease (PVD)?

What is the role of MRI in the workup of peripheral vascular disease (PVD)?

What is the role of CT scanning in the workup of peripheral vascular disease (PVD)?

What is the role of CT angiography (CTA) in the workup of peripheral vascular disease (PVD)?

What is the role of radionuclide-based molecular imaging in the workup of peripheral vascular disease (PVD)?

What is the role of the ankle-brachial index (ABI) in the workup of peripheral vascular disease (PVD)?

How is an ankle-brachial index (ABI) test performed in the workup of peripheral vascular disease (PVD)?

What is the role of transcutaneous oximetry in the workup of peripheral vascular disease (PVD)?

What is the role of ECG in the workup of peripheral vascular disease (PVD)?

Treatment

What are the approach consideration in the treatment of peripheral vascular disease (PVD)?

How are statins used to treat peripheral vascular disease (PVD)?

Which procedures may be indicated in the treatment of peripheral vascular disease (PVD) when conservative measures are not effective?

What is the role of growth factor and cell therapy in the treatment of peripheral vascular disease (PVD)?

What is the prehospital care for peripheral vascular disease (PVD)?

What is the initial emergency department care for peripheral vascular disease (PVD)?

How are thrombi and emboli treated in patients with peripheral vascular disease (PVD)?

When is surgical consultation indicated for acute limb ischemia associated with peripheral vascular disease (PVD)?

How is aortoiliac disease treated in patients with peripheral vascular disease (PVD)?

How is arteriostenosis treated in patients with peripheral vascular disease (PVD)?

How is pain managed in patients with peripheral vascular disease (PVD)?

What is the long-term monitoring of patients with peripheral vascular disease (PVD) who do not require inpatient treatment?

When should emergency department physicians consult with the primary care providers of patients with peripheral vascular disease (PVD)?

Guidelines

What are the AHA and ACC guidelines on peripheral vascular disease (PVD)?

Medications

What is the goal of drug treatment for peripheral vascular disease (PVD)?

Which medications in the drug class Anticoagulants are used in the treatment of Peripheral Vascular Disease?